ArticleBiochemical pharmacology2007
Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area.
Article in Biochemical pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Bupropion increases activation in nucleus accumbens during anticipation of monetary reward.Psychopharmacology · 2019Trial
- Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use.Addiction (Abingdon, England) · 2014Trial
- Bupropion response on sleep quality in patients with depression: implications for increased cardiovascular disease risk.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2014Trial
- Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers.Archives of general psychiatry · 2011Trial
- Neuropharmacology of Nicotine Addiction and Therapeutic Strategies for Smoking Cessation.Biology · 2026Review
- Immediate and Sustained Decrease in Smoking Urges After Acute Insular Cortex Damage.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2017Observational
- Smoking cessation behaviors three months following acute insular damage from stroke.Addictive behaviors · 2015Article
- Microinfusion of bupropion inhibits putative GABAergic neuronal activity of the ventral tegmental area.Basic and clinical neuroscience · 2014Article
- The dynamics of DNA methylation in schizophrenia and related psychiatric disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Review
- Local application of drugs to study nicotinic acetylcholine receptor function in mouse brain slices.Journal of visualized experiments : JoVE · 2012Article
- The CHRNA5/A3/B4 gene cluster and tobacco, alcohol, cannabis, inhalants and other substance use initiation: replication and new findings using mixture analyses.Behavior genetics · 2012Article
- Antidepressants may mitigate the effects of prenatal maternal anxiety on infant auditory sensory gating.The American journal of psychiatry · 2012Article
- Mammalian nicotinic acetylcholine receptors: from structure to function.Physiological reviews · 2009Review
- Individual differences in oral nicotine intake in rats.NeuropharmacologyArticle
- The Response of Ventral Tegmental Area Dopaminergic Neurons to Bupropion: Excitation or Inhibition?Basic and clinical neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Each year, tobacco use causes over 4 million deaths worldwide and billions of dollars are spent on treatment for tobacco-related illness. Bupropion, an atypical antidepressant, improves the rates of successful smoking cessation, however, the mechanisms by which bupropion reduces cigarette smoking and depression are unknown. Here we show that clinical concentrations of bupropion inhibit nicotine's stimulatory effects on brain reward areas. Many drugs of abuse, including nicotine, stimulate dopamine (DA) release in the mesoaccumbens reward system. Nicotinic acetylcholine receptors in the ventral tegmental area (VTA) mediate nicotine's stimulation of DA release, as well as its rewarding effects. Nicotinic receptors are expressed by excitatory and inhibitory neurons that control DA neuron excitability, and by the DA neurons themselves. Bupropion is a broad-spectrum non-competitive nicotinic receptor antagonist. Here we report that pre-treatment of brain slices with a clinically relevant concentration of bupropion dramatically reduces the effects of nicotine on DA neuron excitability. Nicotinic receptors on VTA DA neurons and their synaptic inputs are inhibited by 75 - 95% after bupropion treatment. We also find that bupropion alone reduces GABAergic transmission to DA neurons, thereby diminishing tonic inhibition of these neurons. This increases DA neuron excitability during bupropion treatment in the absence of nicotine, and may contribute to bupropion's antidepressant actions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.